MetaCap

Cencora (COR) vs McKesson (MCK)

Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Nov 22, 2026.

Summary

McKesson (MCK) has outperformed Cencora (COR) over the past year, gaining 23.5% versus a loss of 7.3%. Over five years, MCK leads with a +382.6% price change compared with +182.0% for COR. McKesson is the larger company by market cap ($123.47 billion vs $64.71 billion), about 1.9 times the size.

On valuation, Cencora trades at a lower forward P/E (15.6x vs 20.4x for McKesson). Cencora offers the higher dividend yield (0.71% vs 0.32%). McKesson converts more of its revenue into profit, with a net margin of 1.2% versus 0.5%.

Summary generated from market data by MetaCap's automated system. Methodology

Relative performance

COR-7.27%MCK+23.49%
+31%-2%-34%
Nov 21, 20251 yearNov 20, 2026
COR+181.36%MCK+384.12%
+419%+198%-23%
Nov 15, 20215 yearsNov 16, 2026

Percent change in share price from the first common trading day shown; excludes dividends.

Head-to-head

COR versus MCK key metrics
MetricCORMCK
Share price$339.09$1,069.43
Market cap$64.71B$123.47B
1-day change-0.63%+0.68%
YTD return+0.40%+30.37%
1-year return-7.27%+23.49%
5-year return+182.03%+382.57%
P/E ratio (TTM)18.8927.58
Forward P/E15.6020.39
EPS (TTM)$17.95$38.77
Dividend yield0.71%0.32%
Annual dividend$2.40$3.40
Revenue (latest FY)$321.33B$403.43B
Revenue growth (YoY)+9.31%+12.36%
Net income (latest FY)$1.55B$4.76B
Gross margin3.57%3.61%
Operating margin0.82%1.54%
Net margin0.48%1.18%
52-week high$377.54$1,121.50
52-week low$244.82$723.68
Distance from 52-week high-10.18%-4.64%
Analyst consensusbuybuy
Avg. price target upside+12.78%+8.57%
Average volume1.29M790.59K
Shares outstanding190.83M115.46M
Employees47,00041,600
SectorHealth CareHealth Care
IndustryOther PharmaceuticalsOther Pharmaceuticals

Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.

Key differences

  • MCK has outperformed COR by 30.8 percentage points over the past year.
  • McKesson trades at a higher earnings multiple (27.6x vs 18.9x trailing P/E).

About Cencora

COR stock →

Cencora, Inc. sources and distributes pharmaceutical products in the United States and internationally.

Health Care · Other Pharmaceuticals · 47,000 employees

About McKesson

MCK stock →

McKesson Corporation provides healthcare services in the United States and internationally. It operates through four segments: North American Pharmaceutical, Oncology & Multispecialty, Prescription Technology Solutions, and Medical-Surgical Solutions.

Health Care · Other Pharmaceuticals · 41,600 employees

COR vs MCK FAQ

Which is bigger, Cencora or McKesson?

McKesson (MCK) is larger, with a market capitalization of $123.47B compared with $64.71B for Cencora (COR).

Which stock has performed better over the past year, COR or MCK?

MCK returned +23.49% over the past 12 months, compared with -7.27% for COR (price return, excluding dividends). Past performance does not predict future results.

Which has the lower P/E ratio, COR or MCK?

COR has the lower trailing P/E at 18.9, versus 27.6 for MCK. A lower P/E is not by itself a sign of a better investment; it can reflect slower expected growth or higher risk.

Which pays a higher dividend, Cencora or McKesson?

Cencora has the higher yield at 0.71%, compared with 0.32% for McKesson.

Are Cencora and McKesson in the same industry?

Yes. Both are classified in the Other Pharmaceuticals industry within the Health Care sector.

More comparisons